Pre-Existing COVID-19 / SARS-CoV-2 Immunity Found in Uninfected Individuals
By HospiMedica International staff writers Posted on 28 Jul 2020 |

Illustration
A study has uncovered the presence of virus-specific T cell immunity in people who recovered from COVID-19 and SARS, as well as in some healthy study subjects who had never been infected by either virus, suggesting that a level of pre-existing SARS-CoV-2 immunity is present in the general population.
The study conducted by scientists from the Duke-NUS Medical School (Singapore), in collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore General Hospital (SGH) and National Centre for Infectious Diseases (NCID) found that SARS-CoV-2-specific T cells are present in all recovered COVID-19 patients, as well as in all subjects who recovered from SARS 17 years ago, and in over 50% of both SARS-CoV-1 and SARS-CoV-2 uninfected individuals tested. The findings suggest infection and exposure to coronaviruses induces long-lasting memory T cells, which could help in the management of the current pandemic and in vaccine development against COVID-19.
The T cells, along with antibodies, are an integral part of the human immune response against viral infections due to their ability to directly target and kill infected cells. The scientists tested subjects who had recovered from COVID-19 and found the presence of SARS-CoV-2-specific T cells in all of them, which suggests that T cells play an important role in this infection. Importantly, the scientists showed that patients who recovered from SARS 17 years ago after the 2003 outbreak, still possess virus-specific memory T cells and displayed cross-immunity to SARS-CoV-2. The scientists will now be conducting a larger study of exposed, uninfected subjects to examine whether T cells can protect against COVID-19 infection or alter the course of infection. They will also be exploring the potential therapeutic use of SARS-CoV-2-specific T cells.
“Our team also tested uninfected healthy individuals and found SARS-CoV-2-specific T cells in more than 50% of them. This could be due to cross-reactive immunity obtained from exposure to other coronaviruses, such as those causing the common cold, or presently unknown animal coronaviruses. It is important to understand if this could explain why some individuals are able to better control the infection,” said Professor Antonio Bertoletti, from Duke-NUS’ Emerging Infectious Diseases (EID) program, who is the corresponding author of this study.
“We have also initiated follow-up studies on the COVID-19 recovered patients, to determine if their immunity as shown in their T cells persists over an extended period of time. This is very important for vaccine development and to answer the question about re-infection,” added Associate Professor Tan Yee Joo from the Department of Microbiology and Immunology at NUS Yong Loo Lin School of Medicine and Joint Senior Principal Investigator, Institute of Molecular and Cell Biology, A*STAR.
“While there have been many studies about SARS-CoV-2, there is still a lot we don’t understand about the virus yet. What we do know is that T cells play an important role in the immune response against viral infections and should be assessed for their role in combating SARS-CoV-2, which has affected many people worldwide. Hopefully, our discovery will bring us a step closer to creating an effective vaccine,” said Associate Professor Jenny Low, Senior Consultant, Department of Infectious Diseases, SGH, and Duke-NUS’ EID program.
Related Links:
Duke-NUS Medical School
The study conducted by scientists from the Duke-NUS Medical School (Singapore), in collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore General Hospital (SGH) and National Centre for Infectious Diseases (NCID) found that SARS-CoV-2-specific T cells are present in all recovered COVID-19 patients, as well as in all subjects who recovered from SARS 17 years ago, and in over 50% of both SARS-CoV-1 and SARS-CoV-2 uninfected individuals tested. The findings suggest infection and exposure to coronaviruses induces long-lasting memory T cells, which could help in the management of the current pandemic and in vaccine development against COVID-19.
The T cells, along with antibodies, are an integral part of the human immune response against viral infections due to their ability to directly target and kill infected cells. The scientists tested subjects who had recovered from COVID-19 and found the presence of SARS-CoV-2-specific T cells in all of them, which suggests that T cells play an important role in this infection. Importantly, the scientists showed that patients who recovered from SARS 17 years ago after the 2003 outbreak, still possess virus-specific memory T cells and displayed cross-immunity to SARS-CoV-2. The scientists will now be conducting a larger study of exposed, uninfected subjects to examine whether T cells can protect against COVID-19 infection or alter the course of infection. They will also be exploring the potential therapeutic use of SARS-CoV-2-specific T cells.
“Our team also tested uninfected healthy individuals and found SARS-CoV-2-specific T cells in more than 50% of them. This could be due to cross-reactive immunity obtained from exposure to other coronaviruses, such as those causing the common cold, or presently unknown animal coronaviruses. It is important to understand if this could explain why some individuals are able to better control the infection,” said Professor Antonio Bertoletti, from Duke-NUS’ Emerging Infectious Diseases (EID) program, who is the corresponding author of this study.
“We have also initiated follow-up studies on the COVID-19 recovered patients, to determine if their immunity as shown in their T cells persists over an extended period of time. This is very important for vaccine development and to answer the question about re-infection,” added Associate Professor Tan Yee Joo from the Department of Microbiology and Immunology at NUS Yong Loo Lin School of Medicine and Joint Senior Principal Investigator, Institute of Molecular and Cell Biology, A*STAR.
“While there have been many studies about SARS-CoV-2, there is still a lot we don’t understand about the virus yet. What we do know is that T cells play an important role in the immune response against viral infections and should be assessed for their role in combating SARS-CoV-2, which has affected many people worldwide. Hopefully, our discovery will bring us a step closer to creating an effective vaccine,” said Associate Professor Jenny Low, Senior Consultant, Department of Infectious Diseases, SGH, and Duke-NUS’ EID program.
Related Links:
Duke-NUS Medical School
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
Mass Manufactured Nanoparticles to Deliver Cancer Drugs Directly to Tumors
Polymer-coated nanoparticles loaded with therapeutic drugs hold significant potential for treating cancers, including ovarian cancer. These particles can be precisely directed to tumors, delivering their... Read more
World’s Smallest Pacemaker Fits Inside Syringe Tip
After heart surgery, many patients require temporary pacemakers either to regulate the heart rate while waiting for a permanent pacemaker or to support normal heart rhythm during recovery.... Read more
AI-Powered, Internet-Connected Medical Devices to Revolutionize Healthcare, Finds Study
A new study suggests that artificial intelligence (AI)-powered, internet-connected medical devices have the potential to transform healthcare by enabling earlier detection of diseases, real-time patient... Read moreSurgical Techniques
view channel
New Transcatheter Valve Found Safe and Effective for Treating Aortic Regurgitation
Aortic regurgitation is a condition in which the aortic valve does not close properly, allowing blood to flow backward into the left ventricle. This results in decreased blood flow from the heart to the... Read more
Minimally Invasive Valve Repair Reduces Hospitalizations in Severe Tricuspid Regurgitation Patients
The tricuspid valve is one of the four heart valves, responsible for regulating blood flow from the right atrium (the heart's upper-right chamber) to the right ventricle (the lower-right chamber).... Read morePatient Care
view channel
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more
Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more
Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
A groundbreaking innovation enables hospitals to significantly improve instrument processing time and throughput in operating rooms (ORs) and sterile processing departments. Turbett Surgical, Inc.... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read morePoint of Care
view channel
Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour
Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read moreBusiness
view channel
Expanded Collaboration to Transform OR Technology Through AI and Automation
The expansion of an existing collaboration between three leading companies aims to develop artificial intelligence (AI)-driven solutions for smart operating rooms with sophisticated monitoring and automation.... Read more